摘要
目的本文旨在进一步探究干扰素α(IFN-α)治疗慢性病毒性肝炎中对肝纤维化的疗效,证实IFN-α的抗纤维化作用;同时从分子水平来探讨阻止肝纤维化进展的机理,为临床防治肝纤维化提供理论依据。方法采用ELISA技术测定20例慢性病毒性肝炎患者IFN-α治疗前后Ⅲ型前胶原(PⅢP)、Ⅳ型胶原(CⅣ)、层粘蛋白(LN)、透明质酸(HA)及血小板衍生生长因子-BB(PDGF-BB)含量。结果实验组20例慢性病毒性肝炎患者经IFN-α治疗后,其血清CⅣ、HA、LN、PDGF-BB含量下降非常显著(P<0.01),血清PⅢP含量亦明显下降(P<0.05)。患者组随着肝病严重程度的加重血清PDGF-BB水平亦随之上升,且血清PDGF-BB水平与PⅢP、CⅣ、LN水平呈正相关。结论IFN-α治疗慢性病毒性肝炎肝纤维化的有效性是肯定的。慢性病毒性肝炎患者血清PDGF-BB水平升高,且其升高与肝纤维化有良好的相关性,可作为观察抗肝纤维化药物疗效的指标。IFN-α抑制PDGF-BB的表达可能是其抗纤维化作用的重要机制之一。
Objective To investigate the effects of Interferon alpha （IFN-α） on patients with chronic viral hepatitis in the anti-fibrosis course, and to try to survey its molecular mechanism in treatment and prevention of hepatic fibrosis. And provide a theoretical basis for its therapy. Methods We studied 20 patients with liver fibrosis caused by chronic viral hepatitis who were treated with IFN-α. Enzyme linked Immunosorbent Assay （ELISA） were used to quantify the serum levels of PDGF-BB,PⅢ P,CⅣ ,LN,HA before and after the therapy. Results After the treatment, the serum levels of C Ⅳ,HA,LN,PDGF-BB were much less than those before treatment（P〈0.01） and the serum levels of P Ⅲ P were less than those before treatment （P〈0.05）. Furthermore, The serum concentration of PDGF-BB increased according to the severity of the disease and had linear correlation with the serum concentration of PⅢP,CⅣ and LN（P〈0.05）. Conclusions This study confirms that interferon alpha therapy is very effective for hepatic fibrosis of chronic viral hepatitis. And the observations shows that the serum concentration of PDGF-BB of patients with chronic viral hepatitis increased and the PDGF-BB levels are closely related to hepatic fibrosis. It is suggested that PDGF-BB may be a novel serum diagnostic index for hepatic fibrosis. Furthermore, anti-fibrosis mechanism of IFN-α partly is probably due to its inhibiting the expression of PDGF-BB.
出处
《药品评价》
CAS
2007年第4期294-297,共4页
Drug Evaluation
